Sign In
Buy CTMX
$3.22
+0.0600 (+1.90%)
At Close: Jun 03, 2026
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics: Cashed Up With Catalysts Ahead
11:32am, Tuesday, 26'th May 2026
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, exten
CytomX Therapeutics to Present at Upcoming June Investor Conferences
08:00am, Thursday, 21'st May 2026
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that managem
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
08:00am, Monday, 18'th May 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointm
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
10:51pm, Thursday, 07'th May 2026
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
08:11pm, Thursday, 07'th May 2026
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
04:15pm, Thursday, 07'th May 2026
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patient
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 30'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
06:28pm, Wednesday, 22'nd Apr 2026
Healthcare companies with different market caps offer different rewards and challenges.
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
04:10am, Friday, 17'th Apr 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders bought 13,090 put options on the stock. This is an increas
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
02:17am, Sunday, 05'th Apr 2026
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two busi
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
03:33am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securit
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
04:14am, Friday, 20'th Mar 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously
Why Is CytomX Therapeutics Stock Falling On Wednesday?
01:06pm, Wednesday, 18'th Mar 2026
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
10:03am, Wednesday, 18'th Mar 2026
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median
